Evidence network for deaths_(OS)

1KEYNOTE-581/CLEAR (mtor), 20211CheckMate 025, 20152IMmotion-151 (PDL1 >1%), 2019 IMmotion-151 (all population), 20192JAVELIN Renal 101( PDL1>1%), 2019 JAVELIN Renal 101 (all population), 20191KEYNOTE-426, 20193CheckMate 214 (intermediate and poor risk), 2017 CheckMate 214 (favorable risk) EXPLORATORY, 2017 CheckMate 214 (all population), 20171CheckMate 9ER, 20211KEYNOTE-564, 01KEYNOTE-581/CLEAR (PDL1), 20211CONTACT-03, 2023atezolizumab plus bevacizumab vs. avelumab plus axitinib 1.24 [0.99; 1.56]1.24 [0.99;1.56]atezolizumab plus bevacizumab vs. avelumab plus axitinib 1.24 [0.99; 1.56]atezolizumab plus bevacizumab vs. everolimus 0.78 [0.57; 1.08]0.78 [0.57;1.08]atezolizumab plus bevacizumab vs. everolimus 0.78 [0.57; 1.08]atezolizumab plus bevacizumab vs. nivolumab alone 1.07 [0.72; 1.60]1.07 [0.72;1.60]atezolizumab plus bevacizumab vs. nivolumab alone 1.07 [0.72; 1.60]atezolizumab plus bevacizumab vs. nivolumab plus cabozantinib 1.50 [0.97; 2.32]1.50 [0.97;2.32]atezolizumab plus bevacizumab vs. nivolumab plus cabozantinib 1.50 [0.97; 2.32]atezolizumab plus bevacizumab vs. nivolumab plus ipilimumab 1.32 [0.99; 1.76]1.32 [0.99;1.76]atezolizumab plus bevacizumab vs. nivolumab plus ipilimumab 1.32 [0.99; 1.76]atezolizumab plus bevacizumab vs. pembrolizumab plus axitinib pembrolizumab plus axitinib better 1.70 [1.17; 2.47]1.70 [1.17;2.47]atezolizumab plus bevacizumab vs. pembrolizumab plus axitinib pembrolizumab plus axitinib better 1.70 [1.17; 2.47]atezolizumab plus bevacizumab vs. pembrolizumab plus lenvatinib 1.37 [0.97; 1.92]1.37 [0.97;1.92]atezolizumab plus bevacizumab vs. pembrolizumab plus lenvatinib 1.37 [0.97; 1.92]atezolizumab plus bevacizumab vs. sunitinib 0.90 [0.76; 1.07]0.90 [0.76;1.07]atezolizumab plus bevacizumab vs. sunitinib 0.90 [0.76; 1.07]avelumab plus axitinib vs. atezolizumab plus bevacizumab 0.80 [0.64; 1.01]0.80 [0.64;1.01]avelumab plus axitinib vs. atezolizumab plus bevacizumab 0.80 [0.64; 1.01]avelumab plus axitinib vs. everolimus avelumab plus axitinib better 0.63 [0.46; 0.86]0.63 [0.46;0.86]avelumab plus axitinib vs. everolimus avelumab plus axitinib better 0.63 [0.46; 0.86]avelumab plus axitinib vs. nivolumab alone 0.86 [0.58; 1.28]0.86 [0.58;1.28]avelumab plus axitinib vs. nivolumab alone 0.86 [0.58; 1.28]avelumab plus axitinib vs. nivolumab plus cabozantinib 1.21 [0.79; 1.85]1.21 [0.79;1.85]avelumab plus axitinib vs. nivolumab plus cabozantinib 1.21 [0.79; 1.85]avelumab plus axitinib vs. nivolumab plus ipilimumab 1.06 [0.80; 1.40]1.06 [0.80;1.40]avelumab plus axitinib vs. nivolumab plus ipilimumab 1.06 [0.80; 1.40]avelumab plus axitinib vs. pembrolizumab plus axitinib 1.37 [0.95; 1.97]1.37 [0.95;1.97]avelumab plus axitinib vs. pembrolizumab plus axitinib 1.37 [0.95; 1.97]avelumab plus axitinib vs. pembrolizumab plus lenvatinib 1.10 [0.79; 1.53]1.10 [0.79;1.53]avelumab plus axitinib vs. pembrolizumab plus lenvatinib 1.10 [0.79; 1.53]avelumab plus axitinib vs. sunitinib avelumab plus axitinib better 0.73 [0.63; 0.84]0.73 [0.63;0.84]avelumab plus axitinib vs. sunitinib avelumab plus axitinib better 0.73 [0.63; 0.84]everolimus vs. atezolizumab plus bevacizumab 1.28 [0.93; 1.75]1.28 [0.93;1.75]everolimus vs. atezolizumab plus bevacizumab 1.28 [0.93; 1.75]everolimus vs. avelumab plus axitinib avelumab plus axitinib better 1.59 [1.17; 2.15]1.59 [1.17;2.15]everolimus vs. avelumab plus axitinib avelumab plus axitinib better 1.59 [1.17; 2.15]everolimus vs. nivolumab alone nivolumab alone better 1.37 [1.07; 1.75]1.37 [1.07;1.75]everolimus vs. nivolumab alone nivolumab alone better 1.37 [1.07; 1.75]everolimus vs. nivolumab plus cabozantinib nivolumab plus cabozantinib better 1.92 [1.19; 3.10]1.92 [1.19;3.10]everolimus vs. nivolumab plus cabozantinib nivolumab plus cabozantinib better 1.92 [1.19; 3.10]everolimus vs. nivolumab plus ipilimumab nivolumab plus ipilimumab better 1.68 [1.18; 2.40]1.68 [1.18;2.40]everolimus vs. nivolumab plus ipilimumab nivolumab plus ipilimumab better 1.68 [1.18; 2.40]everolimus vs. pembrolizumab plus axitinib pembrolizumab plus axitinib better 2.17 [1.42; 3.32]2.17 [1.42;3.32]everolimus vs. pembrolizumab plus axitinib pembrolizumab plus axitinib better 2.17 [1.42; 3.32]everolimus vs. pembrolizumab plus lenvatinib pembrolizumab plus lenvatinib better 1.74 [1.17; 2.59]1.74 [1.17;2.59]everolimus vs. pembrolizumab plus lenvatinib pembrolizumab plus lenvatinib better 1.74 [1.17; 2.59]everolimus vs. sunitinib 1.15 [0.88; 1.50]1.15 [0.88;1.50]everolimus vs. sunitinib 1.15 [0.88; 1.50]nivolumab alone vs. atezolizumab plus bevacizumab 0.93 [0.62; 1.39]0.93 [0.62;1.39]nivolumab alone vs. atezolizumab plus bevacizumab 0.93 [0.62; 1.39]nivolumab alone vs. avelumab plus axitinib 1.16 [0.78; 1.71]1.16 [0.78;1.71]nivolumab alone vs. avelumab plus axitinib 1.16 [0.78; 1.71]nivolumab alone vs. everolimus nivolumab alone better 0.73 [0.57; 0.93]0.73 [0.57;0.93]nivolumab alone vs. everolimus nivolumab alone better 0.73 [0.57; 0.93]nivolumab alone vs. nivolumab plus cabozantinib 1.40 [0.82; 2.40]1.40 [0.82;2.40]nivolumab alone vs. nivolumab plus cabozantinib 1.40 [0.82; 2.40]nivolumab alone vs. nivolumab plus ipilimumab 1.23 [0.80; 1.89]1.23 [0.80;1.89]nivolumab alone vs. nivolumab plus ipilimumab 1.23 [0.80; 1.89]nivolumab alone vs. pembrolizumab plus axitinib 1.58 [0.97; 2.59]1.58 [0.97;2.59]nivolumab alone vs. pembrolizumab plus axitinib 1.58 [0.97; 2.59]nivolumab alone vs. pembrolizumab plus lenvatinib 1.27 [0.80; 2.03]1.27 [0.80;2.03]nivolumab alone vs. pembrolizumab plus lenvatinib 1.27 [0.80; 2.03]nivolumab alone vs. sunitinib 0.84 [0.58; 1.21]0.84 [0.58;1.21]nivolumab alone vs. sunitinib 0.84 [0.58; 1.21]nivolumab plus cabozantinib vs. atezolizumab plus bevacizumab 0.67 [0.43; 1.03]0.67 [0.43;1.03]nivolumab plus cabozantinib vs. atezolizumab plus bevacizumab 0.67 [0.43; 1.03]nivolumab plus cabozantinib vs. avelumab plus axitinib 0.83 [0.54; 1.27]0.83 [0.54;1.27]nivolumab plus cabozantinib vs. avelumab plus axitinib 0.83 [0.54; 1.27]nivolumab plus cabozantinib vs. everolimus nivolumab plus cabozantinib better 0.52 [0.32; 0.84]0.52 [0.32;0.84]nivolumab plus cabozantinib vs. everolimus nivolumab plus cabozantinib better 0.52 [0.32; 0.84]nivolumab plus cabozantinib vs. nivolumab alone 0.71 [0.42; 1.23]0.71 [0.42;1.23]nivolumab plus cabozantinib vs. nivolumab alone 0.71 [0.42; 1.23]nivolumab plus cabozantinib vs. nivolumab plus ipilimumab 0.88 [0.55; 1.40]0.88 [0.55;1.40]nivolumab plus cabozantinib vs. nivolumab plus ipilimumab 0.88 [0.55; 1.40]nivolumab plus cabozantinib vs. pembrolizumab plus axitinib 1.13 [0.67; 1.91]1.13 [0.67;1.91]nivolumab plus cabozantinib vs. pembrolizumab plus axitinib 1.13 [0.67; 1.91]nivolumab plus cabozantinib vs. pembrolizumab plus lenvatinib 0.91 [0.55; 1.49]0.91 [0.55;1.49]nivolumab plus cabozantinib vs. pembrolizumab plus lenvatinib 0.91 [0.55; 1.49]nivolumab plus cabozantinib vs. sunitinib nivolumab plus cabozantinib better 0.60 [0.40; 0.89]0.60 [0.40;0.89]nivolumab plus cabozantinib vs. sunitinib nivolumab plus cabozantinib better 0.60 [0.40; 0.89]nivolumab plus ipilimumab vs. atezolizumab plus bevacizumab 0.76 [0.57; 1.01]0.76 [0.57;1.01]nivolumab plus ipilimumab vs. atezolizumab plus bevacizumab 0.76 [0.57; 1.01]nivolumab plus ipilimumab vs. avelumab plus axitinib 0.94 [0.71; 1.24]0.94 [0.71;1.24]nivolumab plus ipilimumab vs. avelumab plus axitinib 0.94 [0.71; 1.24]nivolumab plus ipilimumab vs. everolimus nivolumab plus ipilimumab better 0.59 [0.42; 0.85]0.59 [0.42;0.85]nivolumab plus ipilimumab vs. everolimus nivolumab plus ipilimumab better 0.59 [0.42; 0.85]nivolumab plus ipilimumab vs. nivolumab alone 0.81 [0.53; 1.25]0.81 [0.53;1.25]nivolumab plus ipilimumab vs. nivolumab alone 0.81 [0.53; 1.25]nivolumab plus ipilimumab vs. nivolumab plus cabozantinib 1.14 [0.72; 1.81]1.14 [0.72;1.81]nivolumab plus ipilimumab vs. nivolumab plus cabozantinib 1.14 [0.72; 1.81]nivolumab plus ipilimumab vs. pembrolizumab plus axitinib 1.29 [0.86; 1.94]1.29 [0.86;1.94]nivolumab plus ipilimumab vs. pembrolizumab plus axitinib 1.29 [0.86; 1.94]nivolumab plus ipilimumab vs. pembrolizumab plus lenvatinib 1.03 [0.71; 1.51]1.03 [0.71;1.51]nivolumab plus ipilimumab vs. pembrolizumab plus lenvatinib 1.03 [0.71; 1.51]nivolumab plus ipilimumab vs. sunitinib nivolumab plus ipilimumab better 0.68 [0.54; 0.86]0.68 [0.54;0.86]nivolumab plus ipilimumab vs. sunitinib nivolumab plus ipilimumab better 0.68 [0.54; 0.86]pembrolizumab plus axitinib vs. atezolizumab plus bevacizumab pembrolizumab plus axitinib better 0.59 [0.40; 0.85]0.59 [0.40;0.85]pembrolizumab plus axitinib vs. atezolizumab plus bevacizumab pembrolizumab plus axitinib better 0.59 [0.40; 0.85]pembrolizumab plus axitinib vs. avelumab plus axitinib 0.73 [0.51; 1.05]0.73 [0.51;1.05]pembrolizumab plus axitinib vs. avelumab plus axitinib 0.73 [0.51; 1.05]pembrolizumab plus axitinib vs. everolimus pembrolizumab plus axitinib better 0.46 [0.30; 0.71]0.46 [0.30;0.71]pembrolizumab plus axitinib vs. everolimus pembrolizumab plus axitinib better 0.46 [0.30; 0.71]pembrolizumab plus axitinib vs. nivolumab alone 0.63 [0.39; 1.03]0.63 [0.39;1.03]pembrolizumab plus axitinib vs. nivolumab alone 0.63 [0.39; 1.03]pembrolizumab plus axitinib vs. nivolumab plus cabozantinib 0.88 [0.52; 1.49]0.88 [0.52;1.49]pembrolizumab plus axitinib vs. nivolumab plus cabozantinib 0.88 [0.52; 1.49]pembrolizumab plus axitinib vs. nivolumab plus ipilimumab 0.78 [0.52; 1.17]0.78 [0.52;1.17]pembrolizumab plus axitinib vs. nivolumab plus ipilimumab 0.78 [0.52; 1.17]pembrolizumab plus axitinib vs. pembrolizumab plus lenvatinib 0.80 [0.52; 1.25]0.80 [0.52;1.25]pembrolizumab plus axitinib vs. pembrolizumab plus lenvatinib 0.80 [0.52; 1.25]pembrolizumab plus axitinib vs. sunitinib pembrolizumab plus axitinib better 0.53 [0.38; 0.74]0.53 [0.38;0.74]pembrolizumab plus axitinib vs. sunitinib pembrolizumab plus axitinib better 0.53 [0.38; 0.74]pembrolizumab plus lenvatinib vs. atezolizumab plus bevacizumab 0.73 [0.52; 1.03]0.73 [0.52;1.03]pembrolizumab plus lenvatinib vs. atezolizumab plus bevacizumab 0.73 [0.52; 1.03]pembrolizumab plus lenvatinib vs. avelumab plus axitinib 0.91 [0.66; 1.26]0.91 [0.66;1.26]pembrolizumab plus lenvatinib vs. avelumab plus axitinib 0.91 [0.66; 1.26]pembrolizumab plus lenvatinib vs. everolimus pembrolizumab plus lenvatinib better 0.57 [0.39; 0.85]0.57 [0.39;0.85]pembrolizumab plus lenvatinib vs. everolimus pembrolizumab plus lenvatinib better 0.57 [0.39; 0.85]pembrolizumab plus lenvatinib vs. nivolumab alone 0.79 [0.49; 1.25]0.79 [0.49;1.25]pembrolizumab plus lenvatinib vs. nivolumab alone 0.79 [0.49; 1.25]pembrolizumab plus lenvatinib vs. nivolumab plus cabozantinib 1.10 [0.67; 1.81]1.10 [0.67;1.81]pembrolizumab plus lenvatinib vs. nivolumab plus cabozantinib 1.10 [0.67; 1.81]pembrolizumab plus lenvatinib vs. nivolumab plus ipilimumab 0.97 [0.66; 1.41]0.97 [0.66;1.41]pembrolizumab plus lenvatinib vs. nivolumab plus ipilimumab 0.97 [0.66; 1.41]pembrolizumab plus lenvatinib vs. pembrolizumab plus axitinib 1.25 [0.80; 1.94]1.25 [0.80;1.94]pembrolizumab plus lenvatinib vs. pembrolizumab plus axitinib 1.25 [0.80; 1.94]pembrolizumab plus lenvatinib vs. sunitinib pembrolizumab plus lenvatinib better 0.66 [0.49; 0.88]0.66 [0.49;0.88]pembrolizumab plus lenvatinib vs. sunitinib pembrolizumab plus lenvatinib better 0.66 [0.49; 0.88]sunitinib vs. atezolizumab plus bevacizumab 1.11 [0.94; 1.31]1.11 [0.94;1.31]sunitinib vs. atezolizumab plus bevacizumab 1.11 [0.94; 1.31]sunitinib vs. avelumab plus axitinib avelumab plus axitinib better 1.38 [1.19; 1.60]1.38 [1.19;1.60]sunitinib vs. avelumab plus axitinib avelumab plus axitinib better 1.38 [1.19; 1.60]sunitinib vs. everolimus 0.87 [0.67; 1.14]0.87 [0.67;1.14]sunitinib vs. everolimus 0.87 [0.67; 1.14]sunitinib vs. nivolumab alone 1.19 [0.83; 1.71]1.19 [0.83;1.71]sunitinib vs. nivolumab alone 1.19 [0.83; 1.71]sunitinib vs. nivolumab plus cabozantinib nivolumab plus cabozantinib better 1.67 [1.12; 2.49]1.67 [1.12;2.49]sunitinib vs. nivolumab plus cabozantinib nivolumab plus cabozantinib better 1.67 [1.12; 2.49]sunitinib vs. nivolumab plus ipilimumab nivolumab plus ipilimumab better 1.46 [1.16; 1.85]1.46 [1.16;1.85]sunitinib vs. nivolumab plus ipilimumab nivolumab plus ipilimumab better 1.46 [1.16; 1.85]sunitinib vs. pembrolizumab plus axitinib pembrolizumab plus axitinib better 1.89 [1.35; 2.63]1.89 [1.35;2.63]sunitinib vs. pembrolizumab plus axitinib pembrolizumab plus axitinib better 1.89 [1.35; 2.63]sunitinib vs. pembrolizumab plus lenvatinib pembrolizumab plus lenvatinib better 1.52 [1.13; 2.03]1.52 [1.13;2.03]sunitinib vs. pembrolizumab plus lenvatinib pembrolizumab plus lenvatinib better 1.52 [1.13; 2.03]everolimussunitinibplacebocabozantinibnivolumab aloneatezolizumab plus bevacizumabavelumab plus axitinibpembrolizumab plus axitinibnivolumab plus ipilimumabatezolizumab alonenivolumab plus cabozantinibpembrolizumab alonepembrolizumab plus lenvatiniblenvatinib plus everolimuslenvatinib in associationatezolizumab plus cabozantinibdirect evidencenetwork meta-analysis
T vs. C everolimussunitinibplacebocabozantinibnivolumab aloneatezolizumab plus bevacizumabavelumab plus axitinibpembrolizumab plus axitinibnivolumab plus ipilimumabatezolizumab alonenivolumab plus cabozantinibpembrolizumab alonepembrolizumab plus lenvatiniblenvatinib plus everolimuslenvatinib in associationatezolizumab plus cabozantinib
everolimus---1.15
0.88; 1.50		NANA1.37
1.07; 1.75		1.28
0.93; 1.75		1.59
1.17; 2.15		2.17
1.42; 3.32		1.68
1.18; 2.40		NA1.92
1.19; 3.10		NA1.74
1.17; 2.59		NANANA
sunitinib0.87
0.67; 1.14		---NANA1.19
0.83; 1.71		1.11
0.94; 1.31		1.38
1.19; 1.60		1.89
1.35; 2.63		1.46
1.16; 1.85		NA1.67
1.12; 2.49		NA1.52
1.13; 2.03		NANANA
placeboNANA---NANANANANANANANANANANANANA
cabozantinibNANANA---NANANANANANANANANANANANA
nivolumab alone0.73
0.57; 0.93		0.84
0.58; 1.21		NANA---0.93
0.62; 1.39		1.16
0.78; 1.71		1.58
0.97; 2.59		1.23
0.80; 1.89		NA1.40
0.82; 2.40		NA1.27
0.80; 2.03		NANANA
atezolizumab plus bevacizumab0.78
0.57; 1.08		0.90
0.76; 1.07		NANA1.07
0.72; 1.60		---1.24
0.99; 1.56		1.70
1.17; 2.47		1.32
0.99; 1.76		NA1.50
0.97; 2.32		NA1.37
0.97; 1.92		NANANA
avelumab plus axitinib0.63
0.46; 0.86		0.73
0.63; 0.84		NANA0.86
0.58; 1.28		0.80
0.64; 1.01		---1.37
0.95; 1.97		1.06
0.80; 1.40		NA1.21
0.79; 1.85		NA1.10
0.79; 1.53		NANANA
pembrolizumab plus axitinib0.46
0.30; 0.71		0.53
0.38; 0.74		NANA0.63
0.39; 1.03		0.59
0.40; 0.85		0.73
0.51; 1.05		---0.78
0.52; 1.17		NA0.88
0.52; 1.49		NA0.80
0.52; 1.25		NANANA
nivolumab plus ipilimumab0.59
0.42; 0.85		0.68
0.54; 0.86		NANA0.81
0.53; 1.25		0.76
0.57; 1.01		0.94
0.71; 1.24		1.29
0.86; 1.94		---NA1.14
0.72; 1.81		NA1.03
0.71; 1.51		NANANA
atezolizumab aloneNANANANANANANANANA---NANANANANANA
nivolumab plus cabozantinib0.52
0.32; 0.84		0.60
0.40; 0.89		NANA0.71
0.42; 1.23		0.67
0.43; 1.03		0.83
0.54; 1.27		1.13
0.67; 1.91		0.88
0.55; 1.40		NA---NA0.91
0.55; 1.49		NANANA
pembrolizumab aloneNANANANANANANANANANANA---NANANANA
pembrolizumab plus lenvatinib0.57
0.39; 0.85		0.66
0.49; 0.88		NANA0.79
0.49; 1.25		0.73
0.52; 1.03		0.91
0.66; 1.26		1.25
0.80; 1.94		0.97
0.66; 1.41		NA1.10
0.67; 1.81		NA---NANANA
lenvatinib plus everolimusNANANANANANANANANANANANANA---NANA
lenvatinib in associationNANANANANANANANANANANANANANA---NA
atezolizumab plus cabozantinibNANANANANANANANANANANANANANANA---

pathologies: 10,93,79,178,152,80 - treatments: 671 result logic

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons